This Review describes the evidence linking the renin–angiotensin system (RAS) to cancer, through its roles in processes such as apoptosis, angiogenesis and tissue remodelling. Could RAS inhibitors currently used in the clinic be retooled to treat cancer?
- Amee J. George
- Walter G. Thomas
- Ross D. Hannan